Jade Biosciences reports positive Phase 1 data for JADE101, advances pipeline

Jade Biosciences disclosed second quarter 2026 results and pipeline updates on August 10, 2026, centered on its lead candidate JADE101, an anti-APRIL monoclonal antibody for IgA nephropathy. The company reported interim Phase 1 findings later presented at the 63rd European Renal Association Congress, showing mean IgA reductions of approximately 70% from baseline after a single 700 mg dose¹, with results suggesting the duration of IgA reductions could support dosing every 12 weeks for maintenance¹. Modeling further indicated IgA reductions greater than 70% at steady state using a single 350 mg subcutaneous maintenance dose every 12 weeks after an initial 700 mg induction dose¹, and the company said JADE101 was well-tolerated across all doses tested¹.

Jade also said dosing has begun in JUNIPER, the Phase 2 trial of JADE101 in IgA nephropathy, with interim data expected in 2027¹. A registrational Phase 3 trial is planned to start in the first half of 2027, pending FDA feedback and requirements¹.

In its second program, Jade said dosing began in the Phase 1 trial of JADE201, an anti-BAFF-R antibody, in rheumatoid arthritis patients, with interim biomarker data expected in 2027¹. For JADE301, an anti-IFN-β antibody for dermatomyositis, the company said a Phase 1 healthy volunteer trial is now expected to start in the fourth quarter of 2026, with interim data expected in the second half of 2027¹.

On finances, Jade said it completed a $172.5 million public offering, extending its expected cash runway into the fourth quarter of 2028¹. As of June 30, 2026, the company held cash, cash equivalents, and investments totaling $461.2 million¹, which it said it believes will fund operations into the fourth quarter of 2028¹.